This oncogenic product is necessary and sufficient for the malignant transformation of hematopoietic cells in-vitro and in-vivo [33] and during CML progression the BCR/ABL1 oncogene persist and its level increases [34–36]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.